You are here:     > Enriching Lives | Innovation and Operational Excellence

Innovation and Operational Excellence  

At Glenmark, we believe in enriching the lives of our stakeholders and the community at large through innovation and continually finding newer ways of doing things - big or small. An incessant focus on innovation and being on the leading edge of technology equips us to directly help people globally to live healthier lives. The innovation spirit enables us to create sustained value and returns for our business partners and shareholders. It also instills a sense of pride and accomplishment among our employees.


Glenmark has 5 state-of-the-art Research & Development Centers, out of which 04 are in India and 01 is in Switzerland

Innovation - The Central Pillar of our Mission, is firmly embedded in all our business decisions, investments and activities. In line with our motto to deliver innovative treatments to meet the unmet medical needs of the world, our drug discovery efforts are focused on the critical areas of pain/inflammation, respiratory, dermatology and oncology among others. The emphasis on researchled innovation is reflected in our robust pipeline of novel molecules as well as numerous patents. We are committed to achieving and maintaining operational excellence in all the spheres of our business activities worldwide. This provides us with the right environment for pursuing innovation and helps us achieve the highest levels of quality and operational efficiency. We endeavor to continually identify and implement opportunities for enhancing our operational excellence. Such initiatives enable us to decrease our environmental impacts and make some of our external stakeholder processes, such as supplier bidding, more effective and transparent

Research and Innovation 

Our state-of-the-art Research & Development Centre in Neuchâtel, Switzerland.

Our Commitment to Research and innovation is underpinned by a dedicated, world-class infrastructure. Glenmark has 5 state-of-the-art Research & Development (R&D) Centers, 4 in India and 1 in Switzerland.
Here are key points pertaining to our research and innovation prowess:

  • Leading player in the discovery of new molecules both NCEs and NBEs
  • Robust pipeline of 7 molecules – 2 NCEs and 5 NBEs in various stages of pre-clinical and clinical development
  • 7 out-licensing deals have been struck with global pharma majors with a total revenue of $217 million
  • Focus on discovery of molecules that are first-in-class
Case Study 


At Glenmark, we have developed a Propritary best-in-class platform, BEAT® that streamlines the design and development of bi-specific antibodies. For the past 20 years, bi-specific antibodies have presented a challenge to the industry, as all bi-specific formats developed until recently have had stability and/or manufacturing issues. With the invention of BEAT® technology, our scientists have now overcome these hurdles and are able to efficiently engineer and manufacture bi-specific antibodies. GBR 1302 is our first clinical development candidate in oncology emerging from our BEAT® platform. It is a bi-specific antibody which, when commercialized will revolutionize the treatment paradigm in breast cancer and will pave the way for discovering more effective treatments in other forms of difficult-totreat cancers. GBR 1342 is the second bi-specific antibody that has emerged from our BEAT® platform, which is also our second clinical candidate targeting an oncology indication.

Case Study 


Another highlight in our gamut of generic products that reflects our motto of enriching lives is the launch and sale of Teneligliptin in India. Teneligliptin is an advanced therapeutic option for diabetes available at affordable cost that has transformed diabetes treatment in India.

  • According to the International Diabetes Federation (IDF), approximately 65.1 million patients are suffering from Diabetes in India and by the year 2035, this number is expected to grow up to 110 million patients
  • Teneligliptin is a selective DPP4 inhibitor that is used in the treatment of Type 2 Diabetes Mellitus, when satisfactory improvement cannot be achieved through diet and exercise, or in combination with diet and exercise
  • As per the American Diabetes Association guidelines of 2014, DPP-4 inhibitors have few side effects, but their costs may be a barrier • Glenmark’s Teneligliptin considerably reduces the cost of diabetes treatment per day for Gliptin therapy
  • Glenmark’s Teneligliptin enables patients who are on alternative therapy (on account of treatment cost) to move to the advanced Gliptin therapy, thus providing access to better medical outcomes.

Intellectual Property 

Recongnizing the Importance of Patents and intellectual property in regulated and semi-regulated markets, our Intellectual Property Division has been increasingly stepping up its efforts to create and protect the intellectual property of the company.

We have more than 600 granted patents in over 70 countries covering innovations in NCEs, NBEs, Novel Drug Delivery Systems (NDDS), APIs and Biologics.

Customers and Stakeholders 

At Glenmark, we are receptive to the needs of our customers and are driven to create longterm shareholder value. We have a structured pharmacovigilance (PV) policy and procedure to address any stakeholder complaint. The organization takes several measures to ensure that all stakeholder complaints are received and addressed promptly. Stakeholders can share their grievances with us through various channels. All complaints received are categorized into Adverse Events (AE) or Product Quality Complaints (PQC), which are then addressed as per defined protocol. Further, we adhere to all applicable local regulatory requirements and promptly respond to any queries from competent local authorities.

Quality and Operational Excellence 

Pharmaceuticals is a highly regulated Industry, this encourages us to think innovatively about varied aspects of operational excellence such as process improvements, material and process quality as well as waste minimization. We have undertaken several internal projects in our quest to achieve and maintain operational excellence. These internal projects have led to operational benefits while continuing to meet the stringent quality standards. We have adopted internationally accepted standards of product quality, purity, efficacy and safety across all our operations.

Eleven of our manufacturing facilities are ISO 14001:2004 certified, while one is OHSAS 18001:2007 certified. Our manufacturing facilities are approved by regulatory bodies such as the US FDA, MHRA UK, WHO-GMP, Canadian TPD, South African MCC and ANVISA of Brazil.

We conduct regular training programs to ensure that our employees implement higher standards to exceed expectations.

At Glenmark, we have adopted a single Quality Management System (QMS) that defines corporate quality standards and systems for the business units associated with pharmaceutical products as well as R&D investigational materials. The QMS covers the complete product life cycle. The QMS is periodically updated based on experience, new regulations and improved scientific understanding. Further, it ensures that our operations comply with the cGMP (Current Good Manufacturing Practices), requirements globally.

At Glenmark, we look at quality as a culture that is built through continuous coaching and training programs for all employees. The quality culture enables us to implement higher standards that go beyond compliance. The emphasis on quality is reflected in the robust learning and development programs for our employees across the organization.

Supply Chain Sustainability 

As a good corporate citizen, one of our key priorities is to conduct business in a transparent and seamless manner. In this context, we have undertaken a strategic move from traditional bidding to e-bidding as part of our supplier bidding process. This is a first of its kind initiative at Glenmark, which is now implemented across the organization. This e-bidding process has enabled us to achieve greater transparency in the procurement process including developing an electronic database of suppliers. Additional benefits of this operational excellence initiative include decrease in our paper consumption that contributes towards conservation of natural resources.

Another initiative undertaken by us in our procurement process is an increased focus on Good Manufacturing Practice (GMP) supplier audits and implementation of Corrective and Preventive Action (CAPA) at the supplier end. This initiative has helped Glenmark in reducing the rejection rate of incoming raw material from 0.4 in FY 2014-15 to 0.3 in FY 2015-16.

During the reporting year, our Senior Leadership initiated a communication on Glenmark’s Environment Health and Safety (EHS) policy to our priority suppliers. This is an important first step in creating awareness on sustainability among our suppliers.

When it comes to sourcing of packaging material, we strive to promote local vendors who are able to meet our quality norms. This creates positive impact on the local economy and reduces the environmental footprint associated with long-distance transportation.